Sisodiya Sanjay M
Department of Clinical and Experimental Epilepsy, Institute of Neurology, UCL, National Hospital for Neurology and Neurosurgery, Box 29, Queen Square, London WC1N 3BG, United Kingdom.
Curr Neurol Neurosci Rep. 2005 Jul;5(4):307-11. doi: 10.1007/s11910-005-0076-2.
Drug resistance is a major clinical problem in epilepsy, affecting one in three patients. It is likely to have a complex multifactorial basis, with environmental and genetic contributions. Knowledge of robust genetic factors underlying drug resistance might both improve prediction and permit the development of novel rational treatments for resistance. A number of genetic association studies have been undertaken examining the effect of a range of candidate genes for resistance. Although some of these candidates have good biologic motivation for mediating resistance, currently there are no common genetic variants proven to generate the common clinical phenomenon of resistance. Much work remains to be done, but the scene is set for exciting developments that will hold therapeutic potential for patients with drug-resistant epilepsy.
耐药性是癫痫领域的一个主要临床问题,影响着三分之一的患者。其产生可能具有复杂的多因素基础,涉及环境和遗传因素。了解耐药性背后强大的遗传因素,可能既有助于改善预测,又能推动开发针对耐药性的新型合理治疗方法。已经开展了多项基因关联研究,以检验一系列耐药性候选基因的作用。尽管其中一些候选基因在介导耐药性方面具有良好的生物学依据,但目前尚无经证实能导致常见耐药临床现象的常见基因变异。仍有许多工作要做,但令人兴奋的进展已拉开序幕,有望为耐药性癫痫患者带来治疗潜力。